EXACT SCIENCES CORP Q2 FY2024 earnings call

Key Achievements

• Screened over 1 million people in a quarter with Cologuard.
• Over 190,000 healthcare providers ordered Exact Sciences' cancer tests.
• Over 350 health systems and oncology centers utilized Exact Nexus.
• Progress on Cologuard Plus, Oncodetect, and pipeline programs like blood-based colon cancer screening and multi-cancer screening tests.
• Record adjusted EBITDA of $110 million, $71 million free cash flow, and recognized as a Great Place to work for the sixth consecutive year.

Segment Details

• Screening revenue grew 15% to $532 million, driven by Cologuard orders and rescreens.
• Precision Oncology revenue grew 7% to $168 million, led by Oncotype DX's 31% international expansion.
• Adjusted EBITDA margin expanded 500 basis points to 15.7% due to volume growth, productivity, and expense controls.

Screening revenue was $532 million, representing a 15% increase year-over-year. Precision Oncology revenue was $168 million, up 7% year-over-year. Screening revenue contributed significantly to the total, with core revenue growth of 13% year-over-year, and Precision Oncology's growth was led by Oncotype DX expanding 31% internationally. Adjusted EBITDA was $110 million, with an adjusted EBITDA margin of 15.7%.

Forward-Looking Statements

• Maintained full-year revenue guidance between $2.81 billion and $2.85 billion.
• Raised adjusted EBITDA guidance to between $335 million and $355 million (12.2% margin at midpoint).
• Expected Q3 total revenue between $705 million and $725 million, with screening revenue between $545 million and $555 million (17% growth midpoint) and Precision Oncology revenue between $160 million and $170 million (6% growth midpoint).

Risks

• Uncertainties in clinical trial outcomes for blood-based colon cancer screening and multi-cancer screening tests.
• Performance challenges compared to competitive tests, potentially affecting adoption.
• Regulatory and payer adoption risks for new tests like Cologuard Plus and Oncodetect, including timeline uncertainties for FDA approval and reimbursement.

Q: On the USPSTF process for colon cancer screening guidelines, what's the timeline?

A: The USPSTF process typically takes 2.5-3 years. Research plans are expected later, with final guidance likely in 2027 or later.

Q: On PCR vs sequencing trade-offs for blood tests, what's the advantage?

A: Exact Sciences' proprietary PCR platform offers a cost advantage and better balance of sensitivity and specificity. The R&D team is skilled at optimizing this trade-off for performance and cost of goods.

Q: On care gap program quantification and sales force expansion, any details?

A: Care gap revenue was higher in the first half of 2024 than all of 2023, with sequential growth expected Q3 to Q4. No specific sales force expansion baked in, but investments in sales and marketing are planned for high-growth areas.

Q: On blood test data release timeline, when will case control and pivotal data be available?

A: Case control data is expected to be shared later in the fall, with pivotal data to follow after processing samples. The team is focused on rigorous scientific validation before releasing results.

Q: On Cologuard Plus pricing crosswalk, rationale for 1.25 times?

A: The crosswalk is based on value delivered, including better performance (lower false positive rate, higher detection of pre-cancerous lesions) and cost savings for the healthcare system. The process is complex, involving multiple factors related to cost of goods and clinical value.